SG10201601913RA - Yeast-brachyury immunotherapeutic compositions - Google Patents
Yeast-brachyury immunotherapeutic compositionsInfo
- Publication number
- SG10201601913RA SG10201601913RA SG10201601913RA SG10201601913RA SG10201601913RA SG 10201601913R A SG10201601913R A SG 10201601913RA SG 10201601913R A SG10201601913R A SG 10201601913RA SG 10201601913R A SG10201601913R A SG 10201601913RA SG 10201601913R A SG10201601913R A SG 10201601913RA
- Authority
- SG
- Singapore
- Prior art keywords
- yeast
- immunotherapeutic compositions
- brachyury immunotherapeutic
- brachyury
- compositions
- Prior art date
Links
- 230000001024 immunotherapeutic effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6006—Cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161453656P | 2011-03-17 | 2011-03-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201601913RA true SG10201601913RA (en) | 2016-05-30 |
Family
ID=46831122
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013068176A SG193396A1 (en) | 2011-03-17 | 2012-03-19 | Yeast-brachyury immunotherapeutic compositions |
| SG10201601913RA SG10201601913RA (en) | 2011-03-17 | 2012-03-19 | Yeast-brachyury immunotherapeutic compositions |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013068176A SG193396A1 (en) | 2011-03-17 | 2012-03-19 | Yeast-brachyury immunotherapeutic compositions |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US9198941B2 (enExample) |
| EP (2) | EP2685995B1 (enExample) |
| JP (4) | JP6068368B2 (enExample) |
| KR (1) | KR102046449B1 (enExample) |
| CN (1) | CN103648513B (enExample) |
| AU (3) | AU2012228937B2 (enExample) |
| BR (1) | BR112013023456B1 (enExample) |
| CA (1) | CA2835475C (enExample) |
| DK (1) | DK2685995T3 (enExample) |
| ES (1) | ES2627979T3 (enExample) |
| HK (1) | HK1245649A1 (enExample) |
| HU (1) | HUE033491T2 (enExample) |
| IL (1) | IL228421B (enExample) |
| MX (1) | MX350661B (enExample) |
| PL (1) | PL2685995T3 (enExample) |
| PT (1) | PT2685995T (enExample) |
| RU (2) | RU2690180C2 (enExample) |
| SG (2) | SG193396A1 (enExample) |
| WO (1) | WO2012125998A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2170384B1 (en) | 2007-07-02 | 2016-04-13 | Etubics Corporation | Methods and compositions for producing an adenovirus vector for use with multiple vaccinations |
| WO2012083302A2 (en) | 2010-12-17 | 2012-06-21 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of human adenovirus-36 infection |
| AU2012214394B2 (en) | 2011-02-12 | 2016-08-11 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis B infection |
| PL2685995T3 (pl) | 2011-03-17 | 2017-10-31 | Globeimmune Inc | Kompozycje immunoterapeutyczne drożdże-Brachyury |
| SG10201605265TA (en) | 2011-06-14 | 2016-08-30 | Globeimmune Inc | Yeast-Based Compositions and Methods for the Treatment or Prevention of Hepatitis Delta Virus Infection |
| CA2844500C (en) | 2011-08-17 | 2022-05-10 | Globeimmune, Inc. | Yeast-muc1 immunotherapeutic compositions and uses thereof |
| HK1209835A1 (en) | 2012-06-26 | 2016-04-08 | Biodesix, Inc. | Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies |
| WO2014031178A1 (en) | 2012-08-24 | 2014-02-27 | Etubics Corporation | Replication defective adenovirus vector in vaccination |
| EP2895191B1 (en) | 2012-09-14 | 2019-06-05 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Brachyury protein, adenoviral vectors encoding brachyury protein, and their use |
| EP2976100B1 (en) * | 2013-03-19 | 2020-07-01 | Globeimmune, Inc. | Yeast-based immunotherapy for chordoma |
| US9782473B2 (en) | 2013-03-26 | 2017-10-10 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of human immunodeficiency virus infection |
| US9725494B2 (en) * | 2013-05-17 | 2017-08-08 | United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Soluble CD27 (sCD27) and the use thereof |
| TWI654200B (zh) | 2013-08-30 | 2019-03-21 | 環球免疫公司 | 治療或預防結核病的組合物及方法 |
| EP3129036B1 (en) | 2014-04-11 | 2021-08-11 | Globeimmune, Inc. | Yeast-based immunotherapy and type i interferon sensitivity |
| US11352642B2 (en) | 2015-01-09 | 2022-06-07 | Etubics Corporation | Methods and compositions for combination immunotherapy |
| WO2016172249A1 (en) | 2015-04-20 | 2016-10-27 | Etubics Corporation | Methods and compositions for combination immunotherapy |
| TWI748957B (zh) * | 2015-08-03 | 2021-12-11 | 美商環球免疫公司 | 經修飾之酵母-短尾畸型（Ｂｒａｃｈｙｕｒｙ）免疫治療組合物 |
| AU2016302237B2 (en) | 2015-08-03 | 2022-08-04 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Brachyury deletion mutants, non-yeast vectors encoding brachyury deletion mutants, and their use |
| CN109563521A (zh) | 2016-03-24 | 2019-04-02 | 河谷细胞有限公司 | 用于新表位呈递的序列排列和序列 |
| JP6983819B2 (ja) * | 2016-06-03 | 2021-12-17 | エトゥビクス コーポレーション | 前立腺がん関連抗原を使用する腫瘍ワクチン接種用の組成物及び方法 |
| EP3541400B1 (en) * | 2016-11-18 | 2025-05-14 | Sanford Burnham Prebys Medical Discovery Institute | Gut microbiota and treatment of cancer |
| IL270132B2 (en) | 2017-04-24 | 2024-12-01 | Nantcell Inc | Neoepitope vectors and methods for them |
| KR20220068272A (ko) * | 2017-08-15 | 2022-05-25 | 난트셀, 인크. | Hank 세툭시맙 조합 및 방법 |
| CN119818663A (zh) | 2018-05-15 | 2025-04-15 | 全球免疫公司 | 用于诱导细胞免疫应答的重组酵母裂解物 |
| US20210284716A1 (en) | 2020-03-11 | 2021-09-16 | Immunitybio, Inc. | ACE2-Fc Trap |
| US11857620B2 (en) | 2020-03-11 | 2024-01-02 | Immunitybio, Inc. | Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus |
| US12285480B2 (en) | 2020-03-11 | 2025-04-29 | Nantcell, Inc. | Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses |
| JP2024511277A (ja) | 2021-02-19 | 2024-03-13 | メビオン・メディカル・システムズ・インコーポレーテッド | 粒子線治療システムのためのガントリー |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1036329A (en) | 1908-11-19 | 1912-08-20 | Edison Inc Thomas A | Phonograph-reproducer. |
| FR2486400B1 (fr) | 1980-07-09 | 1986-05-30 | Univablot | Medicaments a base de levures ou de leurs extraits insolubles |
| NZ199722A (en) | 1981-02-25 | 1985-12-13 | Genentech Inc | Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain |
| US4775622A (en) | 1982-03-08 | 1988-10-04 | Genentech, Inc. | Expression, processing and secretion of heterologous protein by yeast |
| US5310654A (en) | 1985-07-31 | 1994-05-10 | The Board Of Trustees Of The Leland Stanford Junior University | Method for determining virulence of Yersinia |
| US5234830A (en) | 1988-02-03 | 1993-08-10 | Suntory Limited | DNA encoding a KEX2 endoprotease without a C-terminal hydrophobic region |
| IL95019A0 (en) | 1989-08-09 | 1991-06-10 | Mycogen Corp | Process for encapsulation of biologicals |
| US5413914A (en) | 1993-07-07 | 1995-05-09 | The Regents Of The University Of Colorado | Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases |
| US5830463A (en) | 1993-07-07 | 1998-11-03 | University Technology Corporation | Yeast-based delivery vehicles |
| US5858378A (en) | 1996-05-02 | 1999-01-12 | Galagen, Inc. | Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen |
| US20020044948A1 (en) | 2000-03-15 | 2002-04-18 | Samir Khleif | Methods and compositions for co-stimulation of immunological responses to peptide antigens |
| AU1951001A (en) | 2000-04-06 | 2001-09-17 | Panacea Pharm Llc | Microbial delivery system |
| US7083787B2 (en) | 2000-11-15 | 2006-08-01 | Globeimmune, Inc. | Yeast-dendritic cell vaccines and uses thereof |
| US7439042B2 (en) | 2002-12-16 | 2008-10-21 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
| CA2508957C (en) | 2002-12-16 | 2015-11-17 | Globeimmune, Inc. | Yeast-based vaccines as immunotherapy |
| JP2009500454A (ja) | 2005-07-11 | 2009-01-08 | グローブイミューン， インコーポレイテッド | 標的化治療の変異型を回避する免疫応答を惹起するための組成物および方法 |
| US20070172503A1 (en) | 2005-12-13 | 2007-07-26 | Mycologics,Inc. | Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines |
| SG169375A1 (en) * | 2006-02-02 | 2011-03-30 | Globeimmune Inc | Yeast-based vaccine for inducing an immune response |
| WO2007133835A2 (en) * | 2006-03-27 | 2007-11-22 | Globeimmune, Inc. | Ras mutation and compositions and mehods related thereto |
| CN104120086A (zh) | 2007-02-02 | 2014-10-29 | 环球免疫公司 | 用于生产基于酵母的疫苗的方法 |
| CA2678404C (en) | 2007-02-28 | 2019-03-19 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Brachyury polypeptides and methods for use |
| WO2008115610A1 (en) | 2007-03-19 | 2008-09-25 | Globeimmune, Inc. | Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer |
| WO2009042642A2 (en) | 2007-09-24 | 2009-04-02 | President And Fellows Of Harvard College | Compositions and methods for the treatment and prevention of ulcerative colitis and colon cancer |
| EP2331125A4 (en) | 2008-09-19 | 2013-03-27 | Globeimmune Inc | IMMUNOTHERAPY FOR CHRONIC HEPATITIS C-VIRUS INFECTIONS |
| WO2010065626A1 (en) | 2008-12-02 | 2010-06-10 | Globeimmune, Inc. | Genotyping tools, methods and kits |
| KR101781966B1 (ko) * | 2009-04-17 | 2017-09-27 | 글로브이뮨 | 암에 대한 병용 면역요법 조성물 및 방법 |
| US8911722B2 (en) | 2009-09-14 | 2014-12-16 | The Regents Of The University Of Colorado, A Body Corporate | Modulation of yeast-based immunotherapy products and responses |
| JP2013522302A (ja) | 2010-03-14 | 2013-06-13 | グローブイミューン，インコーポレイテッド | 酵母系免疫療法を使用した感染症の薬理ゲノミクス及び治療反応性ガイド治療 |
| WO2012019127A2 (en) * | 2010-08-05 | 2012-02-09 | The Regents Of The University Of Colorado | Combination yeast-based immunotherapy and arginine therapy for the treatment of myeloid-derived supressor cell-associated diseases |
| WO2012083302A2 (en) | 2010-12-17 | 2012-06-21 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of human adenovirus-36 infection |
| AU2012214394B2 (en) | 2011-02-12 | 2016-08-11 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis B infection |
| PL2685995T3 (pl) | 2011-03-17 | 2017-10-31 | Globeimmune Inc | Kompozycje immunoterapeutyczne drożdże-Brachyury |
| SG10201605265TA (en) | 2011-06-14 | 2016-08-30 | Globeimmune Inc | Yeast-Based Compositions and Methods for the Treatment or Prevention of Hepatitis Delta Virus Infection |
| CA2844500C (en) | 2011-08-17 | 2022-05-10 | Globeimmune, Inc. | Yeast-muc1 immunotherapeutic compositions and uses thereof |
-
2012
- 2012-03-19 PL PL12757534T patent/PL2685995T3/pl unknown
- 2012-03-19 WO PCT/US2012/029636 patent/WO2012125998A1/en not_active Ceased
- 2012-03-19 SG SG2013068176A patent/SG193396A1/en unknown
- 2012-03-19 RU RU2017116350A patent/RU2690180C2/ru active
- 2012-03-19 AU AU2012228937A patent/AU2012228937B2/en active Active
- 2012-03-19 EP EP12757534.8A patent/EP2685995B1/en active Active
- 2012-03-19 CN CN201280023412.6A patent/CN103648513B/zh active Active
- 2012-03-19 SG SG10201601913RA patent/SG10201601913RA/en unknown
- 2012-03-19 MX MX2013010475A patent/MX350661B/es active IP Right Grant
- 2012-03-19 CA CA2835475A patent/CA2835475C/en active Active
- 2012-03-19 RU RU2013146324A patent/RU2619850C2/ru active IP Right Revival
- 2012-03-19 HU HUE12757534A patent/HUE033491T2/en unknown
- 2012-03-19 PT PT127575348T patent/PT2685995T/pt unknown
- 2012-03-19 BR BR112013023456-3A patent/BR112013023456B1/pt active IP Right Grant
- 2012-03-19 ES ES12757534.8T patent/ES2627979T3/es active Active
- 2012-03-19 JP JP2013558234A patent/JP6068368B2/ja active Active
- 2012-03-19 KR KR1020137027169A patent/KR102046449B1/ko active Active
- 2012-03-19 EP EP17154014.9A patent/EP3238731B1/en active Active
- 2012-03-19 DK DK12757534.8T patent/DK2685995T3/en active
-
2013
- 2013-03-14 US US13/803,719 patent/US9198941B2/en active Active
- 2013-09-12 IL IL228421A patent/IL228421B/en active IP Right Grant
-
2015
- 2015-10-29 US US14/926,372 patent/US9623097B2/en active Active
-
2016
- 2016-12-22 JP JP2016249307A patent/JP6309607B2/ja active Active
-
2017
- 2017-02-02 AU AU2017200715A patent/AU2017200715B2/en active Active
- 2017-03-09 US US15/454,176 patent/US10363294B2/en active Active
-
2018
- 2018-03-14 JP JP2018046148A patent/JP6580733B2/ja active Active
- 2018-04-19 HK HK18105126.6A patent/HK1245649A1/en unknown
- 2018-04-30 AU AU2018202972A patent/AU2018202972B2/en active Active
-
2019
- 2019-04-19 US US16/389,235 patent/US11944673B2/en active Active
- 2019-08-28 JP JP2019155138A patent/JP2019199484A/ja active Pending
-
2020
- 2020-12-21 US US17/129,633 patent/US11938175B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL228421A0 (en) | Immunotherapeutic compositions against yeast brachyury protein | |
| ZA201404448B (en) | Peracid-generating compositions | |
| IL230863A0 (en) | Immunotherapeutic compositions of 1muc-shemer and their uses | |
| GB201117619D0 (en) | Compositions | |
| ZA201400330B (en) | Novel composition | |
| SG11201401335QA (en) | Compositions | |
| GB201117621D0 (en) | Compositions | |
| GB2496447B (en) | Compositions | |
| GB201110833D0 (en) | Compositions | |
| EP2702100A4 (en) | INSULATION COMPOSITIONS | |
| GB201103942D0 (en) | Compositions | |
| GB201103964D0 (en) | Composition | |
| GB201110132D0 (en) | compositions | |
| GB201104849D0 (en) | Compositions | |
| EP2711011A4 (en) | COMPOSITION CONTAINING PANAXADIOL | |
| GB201121300D0 (en) | Novel composition | |
| GB201114930D0 (en) | Novel compositions | |
| GB201108810D0 (en) | Novel compositions | |
| GB201122214D0 (en) | Compositions | |
| GB201104202D0 (en) | Compositions | |
| GB201122216D0 (en) | Compositions | |
| GB201103670D0 (en) | Compositions | |
| GB201121028D0 (en) | Compositions | |
| GB201103941D0 (en) | Compositions | |
| GB201104200D0 (en) | Compositions |